Two MSK physician-researchers were profiled in the media last month.
Fast Company spoke with Dr. Luis Diaz, Jr., Head of the Division of Solid Tumor Oncology. Dr. Diaz co-led a clinical trial of an immunotherapy for rectal cancer that proved effective without the need for surgery in all 14 participating patients. He aims to expand this research to cancers that are usually treated by extensive, life-altering surgeries, like esophageal, pancreatic, and stomach malignancies.
Becker’s Hospital Review interviewed Dr. Michael Postow, Chief of MSK’s Melanoma Service. Dr. Postow is excited about the growing efficacy of immunotherapies and the progress vaccines are making in cancer care. His research is motivated in part by the awareness that current treatment modalities do not yet help every patient; we have miles to go to improve care for everyone.